APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endoparasiticide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Endoparasiticide Market Outlook and Growth Opportunities 2026

31 December 2025199 pages

Choose your research edition.

Industry ResearchEndoparasiticide Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Endoparasiticide Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Endoparasiticide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endoparasiticide Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Endoparasiticide Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Endoparasiticide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Endoparasiticide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Endoparasiticide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Endoparasiticide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Endoparasiticide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Endoparasiticide market include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Endoparasiticide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Endoparasiticide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Endoparasiticide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Endoparasiticide market size, projected growth trends, production technologies, key applications, and end-use industries.

Endoparasiticide Segment by Company

Novartis AG

Merck

Eli Lilly

Bayer AG

Zoetis

Virbac

Vetoquinol

Elanco

Ceva Sante Animlae

Boehringer Ingelheim

Endoparasiticide Segment by Type

Ear Tags

Feed Additives

Tablets

Injectables

Endoparasiticide Segment by Application

Veterinary Hospitals or Clinics

Home Care Settings

Animal Farms

Endoparasiticide Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Endoparasiticide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Endoparasiticide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Endoparasiticide significant trends, drivers, influence factors in global and regions.

6. To analyze Endoparasiticide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Endoparasiticide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endoparasiticide industry.

Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Endoparasiticide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Endoparasiticide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Endoparasiticide Industry Trends Table 2. Endoparasiticide Industry Drivers Table 3. Endoparasiticide Industry Opportunities and Challenges Table 4. Endoparasiticide Industry Restraints Table 5. Global Endoparasiticide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Endoparasiticide Revenue Share by Company (2021-2026) Table 7. Global Endoparasiticide Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Endoparasiticide Sales Volume Share by Company (2021-2026) Table 9. Global Endoparasiticide Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Endoparasiticide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Endoparasiticide Key Company Manufacturing Base & Headquarters Table 12. Global Endoparasiticide Company, Product Type & Application Table 13. Global Endoparasiticide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Endoparasiticide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ear Tags Table 18. Significant Companies of Feed Additives Table 19. Significant Companies of Tablets Table 20. Significant Companies of Injectables Table 21. Global Endoparasiticide Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Endoparasiticide Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Endoparasiticide Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Endoparasiticide Sales Volume Share by Type (2021-2026) Table 25. Global Endoparasiticide Sales Volume Share by Type (2027-2032) Table 26. Global Endoparasiticide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Endoparasiticide Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Endoparasiticide Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Endoparasiticide Sales Value Share by Type (2021-2026) Table 30. Global Endoparasiticide Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Veterinary Hospitals or Clinics Table 32. Significant Companies of Home Care Settings Table 33. Significant Companies of Animal Farms Table 34. Global Endoparasiticide Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Endoparasiticide Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Endoparasiticide Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Endoparasiticide Sales Volume Share by Application (2021-2026) Table 38. Global Endoparasiticide Sales Volume Share by Application (2027-2032) Table 39. Global Endoparasiticide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Endoparasiticide Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Endoparasiticide Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Endoparasiticide Sales Value Share by Application (2021-2026) Table 43. Global Endoparasiticide Sales Value Share by Application (2027-2032) Table 44. Global Endoparasiticide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Endoparasiticide Sales by Region (2021-2026) & (K Units) Table 46. Global Endoparasiticide Sales Market Share by Region (2021-2026) Table 47. Global Endoparasiticide Sales by Region (2027-2032) & (K Units) Table 48. Global Endoparasiticide Sales Market Share by Region (2027-2032) Table 49. Global Endoparasiticide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Endoparasiticide Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Endoparasiticide Sales Value Share by Region (2021-2026) Table 52. Global Endoparasiticide Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Endoparasiticide Sales Value Share by Region (2027-2032) Table 54. Global Endoparasiticide Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Endoparasiticide Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Endoparasiticide Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Endoparasiticide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Endoparasiticide Sales by Country (2021-2026) & (K Units) Table 59. Global Endoparasiticide Sales Market Share by Country (2021-2026) Table 60. Global Endoparasiticide Sales by Country (2027-2032) & (K Units) Table 61. Global Endoparasiticide Sales Market Share by Country (2027-2032) Table 62. Global Endoparasiticide Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Endoparasiticide Sales Value Market Share by Country (2021-2026) Table 64. Global Endoparasiticide Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Endoparasiticide Sales Value Market Share by Country (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Novartis AG Endoparasiticide Product Portfolio Table 70. Novartis AG Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Merck Endoparasiticide Product Portfolio Table 75. Merck Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly Endoparasiticide Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Bayer AG Company Information Table 82. Bayer AG Business Overview Table 83. Bayer AG Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Bayer AG Endoparasiticide Product Portfolio Table 85. Bayer AG Recent Development Table 86. Zoetis Company Information Table 87. Zoetis Business Overview Table 88. Zoetis Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Zoetis Endoparasiticide Product Portfolio Table 90. Zoetis Recent Development Table 91. Virbac Company Information Table 92. Virbac Business Overview Table 93. Virbac Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Virbac Endoparasiticide Product Portfolio Table 95. Virbac Recent Development Table 96. Vetoquinol Company Information Table 97. Vetoquinol Business Overview Table 98. Vetoquinol Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Vetoquinol Endoparasiticide Product Portfolio Table 100. Vetoquinol Recent Development Table 101. Elanco Company Information Table 102. Elanco Business Overview Table 103. Elanco Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Elanco Endoparasiticide Product Portfolio Table 105. Elanco Recent Development Table 106. Ceva Sante Animlae Company Information Table 107. Ceva Sante Animlae Business Overview Table 108. Ceva Sante Animlae Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Ceva Sante Animlae Endoparasiticide Product Portfolio Table 110. Ceva Sante Animlae Recent Development Table 111. Boehringer Ingelheim Company Information Table 112. Boehringer Ingelheim Business Overview Table 113. Boehringer Ingelheim Endoparasiticide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Boehringer Ingelheim Endoparasiticide Product Portfolio Table 115. Boehringer Ingelheim Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Endoparasiticide Distributors List Table 119. Endoparasiticide Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Endoparasiticide Product Image Figure 2. Global Endoparasiticide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Endoparasiticide Sales (2021-2032) & (K Units) Figure 5. Global Endoparasiticide Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Endoparasiticide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ear Tags Image Figure 10. Feed Additives Image Figure 11. Tablets Image Figure 12. Injectables Image Figure 13. Global Endoparasiticide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Endoparasiticide Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Endoparasiticide Sales Volume Share by Type (2021-2032) Figure 16. Global Endoparasiticide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Endoparasiticide Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Endoparasiticide Sales Value Share by Type (2021-2032) Figure 19. Veterinary Hospitals or Clinics Image Figure 20. Home Care Settings Image Figure 21. Animal Farms Image Figure 22. Global Endoparasiticide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Endoparasiticide Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Endoparasiticide Sales Volume Share by Application (2021-2032) Figure 25. Global Endoparasiticide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Endoparasiticide Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Endoparasiticide Sales Value Share by Application (2021-2032) Figure 28. Global Endoparasiticide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Endoparasiticide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Endoparasiticide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Endoparasiticide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 33. North America Endoparasiticide Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Endoparasiticide Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Endoparasiticide Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 39. South America Endoparasiticide Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Endoparasiticide Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Endoparasiticide Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Endoparasiticide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Endoparasiticide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Endoparasiticide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Endoparasiticide Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Endoparasiticide Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Ear Tags
  • Feed Additives
  • Tablets
  • Injectables
Applications
  • Veterinary Hospitals or Clinics
  • Home Care Settings
  • Animal Farms
Companies covered
  • Novartis AG
  • Merck
  • Eli Lilly
  • Bayer AG
  • Zoetis
  • Virbac
  • Vetoquinol
  • Elanco
  • Ceva Sante Animlae
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Endoparasiticide Sales Value (2021-2032)
  4. 1.2.2 Global Endoparasiticide Sales Volume (2021-2032)
  5. 1.2.3 Global Endoparasiticide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Endoparasiticide Market Dynamics
  1. 2.1 Endoparasiticide Industry Trends
  2. 2.2 Endoparasiticide Industry Drivers
  3. 2.3 Endoparasiticide Industry Opportunities and Challenges
  4. 2.4 Endoparasiticide Industry Restraints
3 Endoparasiticide Market by Company
  1. 3.1 Global Endoparasiticide Company Revenue Ranking in 2025
  2. 3.2 Global Endoparasiticide Revenue by Company (2021-2026)
  3. 3.3 Global Endoparasiticide Sales Volume by Company (2021-2026)
  4. 3.4 Global Endoparasiticide Average Price by Company (2021-2026)
  5. 3.5 Global Endoparasiticide Company Ranking (2024-2026)
  6. 3.6 Global Endoparasiticide Company Manufacturing Base and Headquarters
  7. 3.7 Global Endoparasiticide Company Product Type and Application
  8. 3.8 Global Endoparasiticide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Endoparasiticide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Endoparasiticide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Endoparasiticide Market by Type
  1. 4.1 Endoparasiticide Type Introduction
  2. 4.1.1 Ear Tags
  3. 4.1.2 Feed Additives
  4. 4.1.3 Tablets
  5. 4.1.4 Injectables
  6. 4.2 Global Endoparasiticide Sales Volume by Type
  7. 4.2.1 Global Endoparasiticide Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Endoparasiticide Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Endoparasiticide Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Endoparasiticide Sales Value by Type
  11. 4.3.1 Global Endoparasiticide Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Endoparasiticide Sales Value by Type (2021-2032)
  13. 4.3.3 Global Endoparasiticide Sales Value Share by Type (2021-2032)
5 Endoparasiticide Market by Application
  1. 5.1 Endoparasiticide Application Introduction
  2. 5.1.1 Veterinary Hospitals or Clinics
  3. 5.1.2 Home Care Settings
  4. 5.1.3 Animal Farms
  5. 5.2 Global Endoparasiticide Sales Volume by Application
  6. 5.2.1 Global Endoparasiticide Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Endoparasiticide Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Endoparasiticide Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Endoparasiticide Sales Value by Application
  10. 5.3.1 Global Endoparasiticide Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Endoparasiticide Sales Value by Application (2021-2032)
  12. 5.3.3 Global Endoparasiticide Sales Value Share by Application (2021-2032)
6 Endoparasiticide Regional Sales and Value Analysis
  1. 6.1 Global Endoparasiticide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Endoparasiticide Sales by Region (2021-2032)
  3. 6.2.1 Global Endoparasiticide Sales by Region: 2021-2026
  4. 6.2.2 Global Endoparasiticide Sales by Region (2027-2032)
  5. 6.3 Global Endoparasiticide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Endoparasiticide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Endoparasiticide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Endoparasiticide Sales Value by Region (2027-2032)
  9. 6.5 Global Endoparasiticide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Endoparasiticide Sales Value (2021-2032)
  12. 6.6.2 North America Endoparasiticide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Endoparasiticide Sales Value (2021-2032)
  15. 6.7.2 Europe Endoparasiticide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Endoparasiticide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Endoparasiticide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Endoparasiticide Sales Value (2021-2032)
  21. 6.9.2 South America Endoparasiticide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Endoparasiticide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Endoparasiticide Sales Value Share by Country, 2025 VS 2032
7 Endoparasiticide Country-level Sales and Value Analysis
  1. 7.1 Global Endoparasiticide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Endoparasiticide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Endoparasiticide Sales by Country (2021-2032)
  4. 7.3.1 Global Endoparasiticide Sales by Country (2021-2026)
  5. 7.3.2 Global Endoparasiticide Sales by Country (2027-2032)
  6. 7.4 Global Endoparasiticide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Endoparasiticide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Endoparasiticide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Endoparasiticide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Endoparasiticide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Endoparasiticide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Endoparasiticide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Endoparasiticide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Endoparasiticide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Endoparasiticide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Endoparasiticide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Endoparasiticide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Endoparasiticide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Endoparasiticide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Endoparasiticide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Endoparasiticide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Endoparasiticide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Endoparasiticide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Endoparasiticide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Endoparasiticide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Endoparasiticide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Endoparasiticide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Endoparasiticide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Endoparasiticide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Endoparasiticide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Endoparasiticide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Endoparasiticide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Endoparasiticide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Endoparasiticide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Endoparasiticide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Endoparasiticide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Endoparasiticide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Endoparasiticide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Endoparasiticide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Endoparasiticide Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Endoparasiticide Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Endoparasiticide Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Endoparasiticide Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Zoetis
  26. 8.5.1 Zoetis Company Information
  27. 8.5.2 Zoetis Business Overview
  28. 8.5.3 Zoetis Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Zoetis Endoparasiticide Product Portfolio
  30. 8.5.5 Zoetis Recent Developments
  31. 8.6 Virbac
  32. 8.6.1 Virbac Company Information
  33. 8.6.2 Virbac Business Overview
  34. 8.6.3 Virbac Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Virbac Endoparasiticide Product Portfolio
  36. 8.6.5 Virbac Recent Developments
  37. 8.7 Vetoquinol
  38. 8.7.1 Vetoquinol Company Information
  39. 8.7.2 Vetoquinol Business Overview
  40. 8.7.3 Vetoquinol Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Vetoquinol Endoparasiticide Product Portfolio
  42. 8.7.5 Vetoquinol Recent Developments
  43. 8.8 Elanco
  44. 8.8.1 Elanco Company Information
  45. 8.8.2 Elanco Business Overview
  46. 8.8.3 Elanco Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Elanco Endoparasiticide Product Portfolio
  48. 8.8.5 Elanco Recent Developments
  49. 8.9 Ceva Sante Animlae
  50. 8.9.1 Ceva Sante Animlae Company Information
  51. 8.9.2 Ceva Sante Animlae Business Overview
  52. 8.9.3 Ceva Sante Animlae Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ceva Sante Animlae Endoparasiticide Product Portfolio
  54. 8.9.5 Ceva Sante Animlae Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Endoparasiticide Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Endoparasiticide Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Endoparasiticide Value Chain Analysis
  2. 9.1.1 Endoparasiticide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Endoparasiticide Sales Mode & Process
  6. 9.2 Endoparasiticide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Endoparasiticide Distributors
  9. 9.2.3 Endoparasiticide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst